← Product Code [GGP](/submissions/HE/subpart-h%E2%80%94hematology-kits-and-packages/GGP) · K050448

# CHROMOPEP PC, CHROMOPEP AT, MODELS 2.5 AND 5 (K050448)

_Horiba Abx · GGP · Sep 23, 2005 · Hematology · SESE_

**Canonical URL:** https://fda.innolitics.com/submissions/HE/subpart-h%E2%80%94hematology-kits-and-packages/GGP/K050448

## Device Facts

- **Applicant:** Horiba Abx
- **Product Code:** [GGP](/submissions/HE/subpart-h%E2%80%94hematology-kits-and-packages/GGP.md)
- **Decision Date:** Sep 23, 2005
- **Decision:** SESE
- **Submission Type:** Traditional
- **Regulation:** 21 CFR 864.7290
- **Device Class:** Class 2
- **Review Panel:** Hematology

## Indications for Use

Chromopep PC is intended for use as an in vitro chromogenic assay for the quantitative determination of Protein C activity in citrated human plasma. Chromopep AT is intended for use as an in vitro chromogenic assay for the quantitative determination of antithrombin activity in citrated human plasma.

## Device Story

Chromopep PC and Chromopep AT are in vitro diagnostic chromogenic assays used to quantify Protein C and antithrombin activity in citrated human plasma. Protein C assay utilizes Agkistrodon c. contortrix snake venom to activate Protein C; rate of hydrolysis of chromogenic substrate pNAPEP 1566TI measured at 405 nm; signal proportional to Protein C level. Antithrombin assay is a kinetic competition assay; heparin-antithrombin complex inhibits Factor Xa; residual Factor Xa hydrolyzes chromogenic substrate; pNA release measured at 405 nm; signal inversely proportional to antithrombin level. Devices are used in clinical laboratory settings by trained personnel. Results assist clinicians in evaluating coagulation status. This submission represents a name and manufacturer change for previously cleared devices; no changes to reagents, formulation, or performance characteristics.

## Clinical Evidence

No new clinical data provided. Performance characteristics were established in original 510(k) submissions K023990 and K023991. The manufacturer confirms no product changes have occurred since original clearance.

## Technological Characteristics

Chromogenic assays. Protein C assay: synthetic substrate, snake venom activator. Antithrombin assay: synthetic substrate, Factor Xa, Tris Heparin buffer. Detection via spectrophotometry at 405 nm. Quantitative measurement based on kinetic hydrolysis rates.

## Predicate Devices

- Chromocheck Protein C ([K023990](/device/K023990.md))
- Chromocheck Antithrombin A T ([K023991](/device/K023991.md))

## Submission Summary (Full Text)

> This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com.
>
> Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/).

{0}

1

510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY
ASSAY ONLY TEMPLATE

A. 510(k) Number:
K050448

B. Purpose for Submission:
To obtain a name change and manufacturer change from Chromocheck Protein C and Chromocheck Antithrombin to Chromopep Protein C and Chromopep Antithrombin.

C. Measurand:
Protein C and Antithrombin

D. Type of Test:
Chromogenic

E. Applicant:
Horiba ABX, Inc.

F. Proprietary and Established Names:
Chromopep PC 2.5 or Chromopep PC 5
Chromopep AT 2.5 or Chromopep AT 5

G. Regulatory Information:
1. Regulation section:
21CFR 864.7290 (Chromopep PC)
21 CFR 864.7060 (Chromopep AT)
2. Classification:
Class II
3. Product code:

{1}

GGP (Chromopep PC)

JBQ (Chromopep AT)

4. Panel:

81 Hematology

H. Intended Use:

1. Intended use(s):

Chromopep PC is intended for use as an *in vitro* chromogenic assay for the quantitative determination of Protein C activity in citrated human plasma.

Chromopep AT PC is intended for use as an *in vitro* chromogenic assay for the quantitative determination of antithrombin activity in citrated human plasma.

2. Indication(s) for use:

Chromopep PC is intended for use as an *in vitro* chromogenic assay for the quantitative determination of Protein C activity in citrated human plasma.

Chromopep AT PC is intended for use as an *in vitro* chromogenic assay for the quantitative determination of antithrombin activity in citrated human plasma.

3. Special conditions for use statement(s):

4. Special instrument requirements:

I. Device Description:

Chromopep Protein C is a chromogenic assay consisting of a synthetic substrate and Protein C activator.

Chromopep Antithrombin assay consists of a synthetic substrate, Factor Xa and a Tris Heparin buffer.

J. Substantial Equivalence Information:

1. Predicate device name(s):

Chromocheck Protein C

Chromocheck Antithrombin

2

{2}

2. Predicate 510(k) number(s):

K023990 (Chromocheck Protein C)

K023991 (Chromocheck Antithrombin)

3. Comparison with predicate:

|  Similarities  |   |   |   |   |
| --- | --- | --- | --- | --- |
|  Item | Device |   | Predicate  |   |
|  Component Reagents | Chromopep PC | Chromopep AT | Chromocheck PC | Chromocheck AT  |
|   |  Same | Same | As provided in original 510(k) | As provided in original 510(k)  |
|  Controls & calibrators | All citrated human plasma (frozen or lyophilized) and validated against an international standard may be used. | Same | Same | Same  |
|  Differences  |   |   |   |   |
| --- | --- | --- | --- | --- |
|  Item | Device |   | Predicate  |   |
|  Labeling | Chromopep PC | Chromopep AT | Chromocheck PC | Chromocheck AT  |
|   |  Chromopep PC specific label | Chromopep AT specific label |  |   |

K. Standard/Guidance Document Referenced (if applicable):

L. Test Principle:

Protein C in plasma is activated by a specific enzyme from Agkistrodon c. contortrix snake venom. The amount of activated protein C (APC) is determined by the rate of hydrolysis of the chromogenic substrate pNAPEP 1566TI. The pNA release measured at 405 nm is proportional to the protein C level in the range from 0-120% of normal plasma.

Chromopep Antithrombin is a kinetic assay based on competition between inhibition of factor Xa by the heparin-antithrombin complex and hydrolysis of a chromogenic

{3}

substrate by factor Xa which is present is excess. The amount of pNA released in the reaction measured at 405 nm is inversely proportional to the amount of antithrombin present and this can be quantified using a calibration curve.

## M. Performance Characteristics (if/when applicable):

*Note: The performance characteristics for Chromopep Protein C 2.5 and Chromopep Protein C 5 were established from the data provided in the original 510(k) K023990 ChromoCheck™ Protein C 25 and ChromoCheck™ Protein C 5 submitted by Precision Biologic, Inc., and cleared on March 19, 2003.

The performance characteristics for Chromopep Antithrombin and Chromopep Antithrombin 5 were established from the data provided in the original 510(k) K023991 ChromoCheck™ Antithrombin 2.5 and ChromoCheck™ Antithrombin 5 submitted by Precision Biologic, Inc., and cleared on April 28, 2003.

Both products are manufactured by Biopep, mauguio, France. No product change has occurred since the original submission.

1. Analytical performance:

Refer to previously cleared 510(k) submissions – K023990 & K023991

a. Precision/Reproducibility:
b. Linearity/assay reportable range:
c. Traceability, Stability, Expected values (controls, calibrators, or methods):
d. Detection limit:
e. Analytical specificity:
f. Assay cut-off:

2. Comparison studies:

Refer to previously cleared 510(k) submissions – K023990 & K023991

a. Method comparison with predicate device:
b. Matrix comparison:

3. Clinical studies:

{4}

Refer to previously cleared 510(k) submissions – K023990 & K023991

a. Clinical Sensitivity:

b. Clinical specificity:

c. Other clinical supportive data (when a. and b. are not applicable):

4. Clinical cut-off:

5. Expected values/Reference range:

The range of the Chromopep PC assay is 5% - 140% protein C activity.

The range of the Chromopep AT assay is 0% - 120% antithrombin activity.

N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.

5

---

**Source:** [https://fda.innolitics.com/submissions/HE/subpart-h%E2%80%94hematology-kits-and-packages/GGP/K050448](https://fda.innolitics.com/submissions/HE/subpart-h%E2%80%94hematology-kits-and-packages/GGP/K050448)

**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).

**Cite:** Innolitics at https://innolitics.com